Forecasted · Grant
Studies Addressing Rare Neurodegenerative Diseases including ALS
Food and Drug Administration, Department of Health and Human Services
Key facts
Copied from the official Grants.gov record. Last verified October 29, 2026.
- Program name
- Studies Addressing Rare Neurodegenerative Diseases including ALS
- Issuing agency
- Food and Drug Administration (Department of Health and Human Services)
- Opportunity number
- FOR-FD-25-006
- Funding type
- Grant
- Funding purpose
- Food and Nutrition, Agriculture, Consumer Protection
- Status
- Forecasted
- Application deadline
- Forecasted · no application dates yet
- Published award range
- Not published by the agency
- Expected number of awards
- 10
- Cost sharing or match required
- No
- Eligible applicants (official categories)
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Unrestricted (open to any type of entity, subject to any clarification in Additional Information on Eligibility)
- Relevant to
- Businesses and NonprofitsHow we determined this: Grants.gov lists eligibility as Unrestricted. Grants.gov eligibility includes small businesses or for-profit organizations. Grants.gov eligibility includes nonprofit organizations.
- Geographic restrictions
- None stated in structured data (federal opportunities are often nationwide). Check the eligibility details and full announcement for any limits.
- Assistance Listing (CFDA)
- 93.103
- Official source
- View on Grants.gov ↗
- Application URL
- www.grants.gov/search-results-detail/356046 ↗Apply through Grants.gov (Workspace) using the application package on the official listing, unless the full announcement names a different submission system.
- Source identifier
- Grants.gov opportunity ID 356046 · Funding opportunity number FOR-FD-25-006
- Posted
- August 14, 2024 · Source last updated August 14, 2024
- Last verified
- October 29, 2026 (against Grants.gov)
- Data completeness
- 75% of key fields published by the sourceNot published: published funding range, eligibility criteria text, application dates.
- Record confidence
- mediumforecast — dates and amounts are agency estimates.
Description (from the official listing)
The purpose of this funding opportunity announcement (FOA) is to support studies that advance medical product development of interventions intended to prevent, diagnose, mitigate, treat, or cure ALS and other rare neurodegenerative diseases in adults and children. Through the support of these studies, FDA expects to address critical knowledge gaps, exert a significant impact on rare neurodegenerative diseases, and to inform current or future product development.
Agency contact
Terrin Brown Grantor
terrin.brown@fda.hhs.gov